Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review)

Uekuri,Chiharu; Shigetomi,Hiroshi; Ono,Sumire; Sasaki,Yoshikazu; Matsuura,Miyuki; Kobayashi,Hiroshi

doi:10.3892/ol.2013.1550

Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review)

Authors:
- Chiharu Uekuri
- Hiroshi Shigetomi
- Sumire Ono
- Yoshikazu Sasaki
- Miyuki Matsuura
- Hiroshi Kobayashi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara 634‑8522, Japan
Published online on: August 28, 2013 https://doi.org/10.3892/ol.2013.1550
Pages: 1163-1173

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometriosis‑associated ovarian cancers demonstrate substantial morphological and genetic diversity. The transcription factor, hepatocyte nuclear factor (HNF)‑1β, may be one of several key genes involved in the identity of ovarian clear cell carcinoma (CCC). The present study reviews a considerably expanded set of HNF‑1β‑associated genes and proteins that determine the pathophysiology of CCC. The current literature was reviewed by searching MEDLINE/PubMed. Functional interpretations of gene expression profiling in CCC are provided. Several important CCC‑related genes overlap with those known to be regulated by the upregulation of HNF‑1β expression, along with a lack of estrogen receptor (ER) expression. Furthermore, the genetic expression pattern in CCC resembles that of the Arias‑Stella reaction, decidualization and placentation. HNF‑1β regulates a subset of progesterone target genes. HNF‑1β may also act as a modulator of female reproduction, playing a role in endometrial regeneration, differentiation, decidualization, glycogen synthesis, detoxification, cell cycle regulation, implantation, uterine receptivity and a successful pregnancy. In conclusion, the present study focused on reviewing the aberrant expression of CCC‑specific genes and provided an update on the pathological implications and molecular functions of well‑characterized CCC‑specific genes.

View Figures

View References

1	Pectasides D, Pectasides E, Psyrri A and Economopoulos T: Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist. 11:1089–1094. 2006. View Article : Google Scholar : PubMed/NCBI
2	Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI
3	Kajihara H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sado T, Oi H and Kobayashi H: Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review). Oncol Rep. 23:1193–1203. 2010.PubMed/NCBI
4	Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK and Konishi I: Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene. 29:1741–1752. 2010. View Article : Google Scholar : PubMed/NCBI
5	Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J and Konishi I: Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett. 310:129–133. 2011. View Article : Google Scholar : PubMed/NCBI
6	Itamochi H, Kigawa J, Akeshima R, Sato S, Kamazawa S, Takahashi M, Kanamori Y, Suzuki M, Ohwada M and Terakawa N: Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology. 62:349–353. 2002. View Article : Google Scholar : PubMed/NCBI
7	Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H and Kobayashi H: Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev. 35:608–615. 2009. View Article : Google Scholar : PubMed/NCBI
8	Higashiura Y, Kajihara H, Shigetomi H and Kobayashi H: Identification of multiple pathways involved in the malignant transformation of endometriosis (Review). Oncol Lett. 4:3–9. 2012.PubMed/NCBI
9	Maeda D and Shih IeM: Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol. 20:45–52. 2013. View Article : Google Scholar : PubMed/NCBI
10	Toyokuni S: Mysterious link between iron overload and CDKN2A/2B. J Clin Biochem Nutr. 48:46–49. 2011. View Article : Google Scholar : PubMed/NCBI
11	Tanase Y, Yamada Y, Shigetomi H, Kajihara H, Oonogi A, Yoshizawa Y, Furukawa N, Haruta S, Yoshida S, Sado T, Oi H and Kobayashi H: Modulation of estrogenic action in clear cell carcinoma of the ovary. Exp Ther Med. 3:18–24. 2012.PubMed/NCBI
12	Kajihara H, Yamada Y, Shigetomi H, Higashiura Y and Kobayashi H: The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear cell-type versus endometrioid-type adenocarcinoma. Int J Gynecol Pathol. 31:304–312. 2012. View Article : Google Scholar : PubMed/NCBI
13	DeLair D, Oliva E, Köbel M, Macias A, Gilks CB and Soslow RA: Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol. 35:36–44. 2011. View Article : Google Scholar : PubMed/NCBI
14	Hecht JL, Kotsopoulos J, Hankinson SE and Tworoger SS: Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses’ Health Study. Cancer Epidemiol Biomarkers Prev. 18:1624–3160. 2009.PubMed/NCBI
15	Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y and Hirohashi S: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 163:2503–2512. 2003. View Article : Google Scholar
16	Uchida H, Maruyama T, Nishikawa-Uchida S, Oda H, Miyazaki K, Yamasaki A and Yoshimura Y: Studies using an in vitro model show evidence of involvement of epithelial-mesenchymal transition of human endometrial epithelial cells in human embryo implantation. J Biol Chem. 287:4441–4450. 2012. View Article : Google Scholar
17	Wareing M and Greenwood SL: Review: Potassium channels in the human fetoplacental vasculature. Placenta. 32:S203–S206. 2011. View Article : Google Scholar
18	Milne SA, Henderson TA, Kelly RW, Saunders PT, Baird DT and Critchley HO: Leukocyte populations and steroid receptor expression in human first-trimester decidua; regulation by antiprogestin and prostaglandin E analog. J Clin Endocrinol Metab. 90:4315–4321. 2005. View Article : Google Scholar : PubMed/NCBI
19	Bulun SE, Cheng YH, Pavone ME, Xue Q, Attar E, Trukhacheva E, Tokunaga H, Utsunomiya H, Yin P, Luo X, Lin Z, Imir G, Thung S, Su EJ and Kim JJ: Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med. 28:36–43. 2010. View Article : Google Scholar : PubMed/NCBI
20	Akahane T, Sekizawa A, Okuda T, Kushima M, Saito H and Okai T: Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer. Int J Gynecol Pathol. 24:369–376. 2005. View Article : Google Scholar : PubMed/NCBI
21	Dhingra N, Punia RS, Radotra A and Mohan H: Arias-Stella reaction in upper genital tract in pregnant and non-pregnant women: a study of 120 randomly selected cases. Arch Gynecol Obstet. 276:47–52. 2007. View Article : Google Scholar : PubMed/NCBI
22	Trpkov K, Guggisberg K and Yilmaz A: Arias-Stella reaction as a diagnostic pitfall in a bladder biopsy with endometriosis: case report and review of the pseudoneoplastic bladder lesions. Pathol Res Pract. 205:653–656. 2009. View Article : Google Scholar : PubMed/NCBI
23	Sakaki M, Hirokawa M, Sano T, Takahashi H, Tezuka K, Abe K and Sano M: Ovarian endometriosis showing decidual change and Arias-Stella reaction with biotin-containing intranuclear inclusions. Acta Cytol. 47:321–324. 2003.
24	Ohkawa K, Amasaki H, Terashima Y, Aizawa S and Ishikawa E: Clear cell carcinoma of the ovary: light and electron microscopic studies. Cancer. 40:3019–3029. 1977. View Article : Google Scholar : PubMed/NCBI
25	Kato N and Motoyama T: Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology. 52:682–688. 2008. View Article : Google Scholar : PubMed/NCBI
26	Matsuura M, Suzuki T and Saito T: Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci. 101:1828–1833. 2010. View Article : Google Scholar : PubMed/NCBI
27	Fraga-Silva RA, Costa-Fraga FP, Murça TM, et al: Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension. 61:1233–1238. 2013. View Article : Google Scholar : PubMed/NCBI
28	Min KW, Park MH, Hong SR, Lee H, Kwon SY, Hong SH, Joo HJ, Park IA, An HJ, Suh KS, Oh HK, Yoo CW, Kim MJ, Chang HK, Jun SY, Yoon HK, Chang ED, Kim DW and Kim I; The Gynecologic Pathology Study Group of the Korean Society of Pathologists. Clear Cell Carcinomas of the Ovary: A Multi-Institutional Study of 129 Cases in Korea With Prognostic Significance of Emi1 and Galectin-3. Int J Gynecol Pathol. 32:3–14. 2013. View Article : Google Scholar : PubMed/NCBI
29	Oishi T, Itamochi H, Kigawa J, Kanamori Y, Shimada M, Takahashi M, Shimogai R, Kawaguchi W, Sato S and Terakawa N: Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer. 17:1040–1046. 2007. View Article : Google Scholar : PubMed/NCBI
30	von Wolff M, Wang X, Gabius HJ and Strowitzki T: Galectin fingerprinting in human endometrium and decidua during the menstrual cycle and in early gestation. Mol Hum Reprod. 11:189–194. 2005.PubMed/NCBI
31	Noël JC, Chapron C, Borghese B, Fayt I and Anaf V: Galectin-3 is overexpressed in various forms of endometriosis. Appl Immunohistochem Mol Morphol. 19:253–257. 2011.PubMed/NCBI
32	Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T and Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 22:824–832. 2009.PubMed/NCBI
33	Tamada Y, Takeuchi H, Suzuki N, Susumu N, Aoki D and Irimura T: Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Sci. 98:1586–1591. 2007. View Article : Google Scholar : PubMed/NCBI
34	Vlad AM, Diaconu I and Gantt KR: MUC1 in endometriosis and ovarian cancer. Immunol Res. 36:229–236. 2006. View Article : Google Scholar : PubMed/NCBI
35	Carson DD, Julian J, Lessey BA, Prakobphol A and Fisher SJ: MUC1 is a scaffold for selectin ligands in the human uterus. Front Biosci. 11:2903–2908. 2006. View Article : Google Scholar : PubMed/NCBI
36	Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, Miyatake T, Fujita M, Lee CM, Morimoto K, Fujimoto M, Kimura T and Naka T: Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer. 125:2316–2322. 2009. View Article : Google Scholar : PubMed/NCBI
37	Ponnampalam AP and Rogers PA: Cyclic changes and hormonal regulation of annexin IV mRNA and protein in human endometrium. Mol Hum Reprod. 12:661–669. 2006. View Article : Google Scholar : PubMed/NCBI
38	Jiang YL, Li B, Xing FQ, Wang F and Feng JH: Study on the relationship between altered expression of annexin A4 and endometrial receptivity during the implantation window in infertile patients with endometriosis. Zhonghua Fu Chan Ke Za Zhi. 47:324–327. 2012.(In Chinese).
39	Sugita S, Morishita Y, Kano J, Furuya S, Shiba-Ishii A and Noguchi M: IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. Histopathology. 58:729–738. 2011. View Article : Google Scholar : PubMed/NCBI
40	Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A and Reis-Filho JS: Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res. 17:1521–1534. 2011. View Article : Google Scholar : PubMed/NCBI
41	Howell NR, Zheng W, Cheng L, Tornos C, Kane P, Pearl M, Chalas E and Liang SX: Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis? Int J Gynecol Pathol. 26:134–140. 2007. View Article : Google Scholar : PubMed/NCBI
42	Pacchiarotti A, Caserta D, Sbracia M and Moscarini M: Expression of oct-4 and c-kit antigens in endometriosis. Fertil Steril. 95:1171–1173. 2011. View Article : Google Scholar : PubMed/NCBI
43	Ghosh D and Sengupta J: Endocrine and paracrine correlates of endometrial receptivity to blastocyst implantation in the human. Indian J Physiol Pharmacol. 48:6–30. 2004.PubMed/NCBI
44	Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N and Feng Y: HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer. 19:1347–1352. 2009. View Article : Google Scholar : PubMed/NCBI
45	Zanatta A, Rocha AM, Carvalho FM, Pereira RM, Taylor HS, Motta EL, Baracat EC and Serafini PC: The role of the Hoxa10/HOXA10 gene in the etiology of endometriosis and its related infertility: a review. J Assist Reprod Genet. 27:701–710. 2010. View Article : Google Scholar : PubMed/NCBI
46	Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T and Oi H: The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer. 19:471–479. 2009. View Article : Google Scholar : PubMed/NCBI
47	Salameh W, Helliwell JP, Han G, McPhaul L and Khorram O: Expression of endometrial glycogen synthase kinase-3beta protein throughout the menstrual cycle and its regulation by progesterone. Mol Hum Reprod. 12:543–549. 2006. View Article : Google Scholar : PubMed/NCBI
48	von Wolff M, Ursel S, Hahn U, Steldinger R and Strowitzki T: Glucose transporter proteins (GLUT) in human endometrium: expression, regulation, and function throughout the menstrual cycle and in early pregnancy. J Clin Endocrinol Metab. 88:3885–3892. 2003.PubMed/NCBI
49	Senkel S, Lucas B, Klein-Hitpass L and Ryffel GU: Identification of target genes of the transcription factor HNF1beta and HNF1alpha in a human embryonic kidney cell line. Biochim Biophys Acta. 1731:179–190. 2005. View Article : Google Scholar : PubMed/NCBI
50	Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY and Sharma MR: Severe irinotecan-induced toxicity in a patient with UGT1A128 and UGT1A16 polymorphisms. World J Gastroenterol. 19:3899–3903. 2013.PubMed/NCBI
51	Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK and Lin JY: Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis. 32:138–145. 2011. View Article : Google Scholar : PubMed/NCBI
52	Salleh N, Baines DL, Naftalin RJ and Milligan SR: The hormonal control of uterine luminal fluid secretion and absorption. J Membr Biol. 206:17–28. 2005. View Article : Google Scholar : PubMed/NCBI
53	Kerschner JL and Harris A: Transcriptional networks driving enhancer function in the CFTR gene. Biochem J. 446:203–212. 2012. View Article : Google Scholar : PubMed/NCBI
54	Ferrè S, Veenstra GJ, Bouwmeester R, Hoenderop JG and Bindels RJ: HNF-1B specifically regulates the transcription of the γa-subunit of the Na+/K+-ATPase. Biochem Biophys Res Commun. 404:284–290. 2011.
55	Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T and Oi H: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (Review). Oncol Rep. 22:233–240. 2009.PubMed/NCBI
56	Gütgemann I, Lehman NL, Jackson PK and Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol. 21:445–454. 2008.PubMed/NCBI
57	Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih IeM and Wang TL: DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res. 16:1997–2008. 2010. View Article : Google Scholar : PubMed/NCBI
58	Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC and Lee HP: Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res. 18:47–56. 2009. View Article : Google Scholar
59	Ozdemir F, Altinisik J, Karateke A, Coksuer H and Buyru N: Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med. 4:1092–1096. 2012.PubMed/NCBI
60	Ho CM, Lai HC, Huang SH, Chien TY, Lin MC and Chang SF: Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur J Clin Invest. 40:310–318. 2010. View Article : Google Scholar : PubMed/NCBI
61	Akatsuka S, Yamashita Y, Ohara H, Liu YT, Izumiya M, Abe K, Ochiai M, Jiang L, Nagai H, Okazaki Y, Murakami H, Sekido Y, Arai E, Kanai Y, Hino O, Takahashi T, Nakagama H and Toyokuni S: Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One. 7:e434032012. View Article : Google Scholar : PubMed/NCBI
62	Choi YL, Kang SY, Shin YK, Choi JS, Kim SH, Lee SJ, Bae DS and Ahn G: Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch. 448:331–336. 2006. View Article : Google Scholar : PubMed/NCBI
63	Vestergaard AL, Thorup K, Knudsen UB, Munk T, Rosbach H, Poulsen JB, Guldberg P and Martensen PM: Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis. Mol Hum Reprod. 17:758–761. 2011. View Article : Google Scholar : PubMed/NCBI
64	Zannoni GF, Morassi F, Prisco MG, De Stefano I, Vellone VG, Arena V, Scambia G and Gallo D: Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors. Int J Gynecol Pathol. 31:507–516. 2012. View Article : Google Scholar : PubMed/NCBI
65	Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L and Cooper K: Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol. 93:379–386. 2006. View Article : Google Scholar : PubMed/NCBI
66	Axiotis CA, Guarch R, Merino MJ, Laporte N and Neumann RD: P-glycoprotein expression is increased in human secretory and gestational endometrium. Lab Invest. 65:577–581. 1991.PubMed/NCBI
67	Nomura H, Tamada Y, Miyagi T, Suzuki A, Taira M, Suzuki N, Susumu N, Irimura T and Aoki D: Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. Oncol Res. 16:289–297. 2006.PubMed/NCBI
68	Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B and Shridhar V: Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res. 69:4843–4850. 2009. View Article : Google Scholar : PubMed/NCBI
69	Collins Y, Dicioccio R, Keitz B, Lele S and Odunsi K: Methylation of death-associated protein kinase in ovarian carcinomas. Int J Gynecol Cancer. 16:195–199. 2006. View Article : Google Scholar : PubMed/NCBI
70	Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM and Wong KK: PAX2 Expression in Ovarian Cancer. Int J Mol Sci. 14:6090–6105. 2013. View Article : Google Scholar : PubMed/NCBI
71	Cai KQ, Caslini C, Capo-chichi CD, Slater C, Smith ER, Wu H, Klein-Szanto AJ, Godwin AK and Xu XX: Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PLoS One. 4:e64542009. View Article : Google Scholar
72	Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F and Montuenga LM: Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia. 9:840–852. 2007. View Article : Google Scholar
73	McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE and Gabra H: The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov. 2:156–171. 2012. View Article : Google Scholar
74	Ren F, Wang D, Jiang Y and Ren F: Epigenetic inactivation of hMLH1 in the malignant transformation of ovarian endometriosis. Arch Gynecol Obstet. 285:215–221. 2012. View Article : Google Scholar : PubMed/NCBI
75	Coffinier C, Thepot D, Babinet C, Yaniv M and Barra J: Essential role for the homeoprotein vHNF1/HNF1beta in visceral endoderm differentiation. Development. 126:4785–4794. 1999.PubMed/NCBI
76	Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y and Bell GI: Mutation in hepatocyte nuclear factor-1β gene (TCF2) associated with MODY. Nat Genet. 17:384–385. 1997.
77	Ogata K, Shimamura Y, Hamada K, Hisa M, Bun M, Okada N, Inoue K, Taniguchi Y, Ishihara M, Kagawa T, Horino T, Fujimoto S and Terada Y: Upregulation of HNF-1β during experimental acute kidney injury plays a crucial role in renal tubule regeneration. Am J Physiol Renal Physiol. 303:F689–F699. 2012.
78	D’Angelo A, Bluteau O, Garcia-Gonzalez MA, Gresh L, Doyen A, Garbay S, Robine S and Pontoglio M: Hepatocyte nuclear factor 1alpha and beta control terminal differentiation and cell fate commitment in the gut epithelium. Development. 137:1573–1582. 2010.PubMed/NCBI
79	Avni FE and Hall M: Renal cystic diseases in children: new concepts. Pediatr Radiol. 40:939–946. 2010. View Article : Google Scholar : PubMed/NCBI
80	Zhou XH, Hui ZY and Li Y: Clinical and pathological features of a neonate with autosomal recessive polycystic kidney disease caused by a nonsense PKHD1 mutation. World J Pediatr. 9:76–79. 2013. View Article : Google Scholar : PubMed/NCBI
81	Serafini-Cessi F, Monti A and Cavallone D: N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases. Glycoconj J. 22:383–394. 2005. View Article : Google Scholar : PubMed/NCBI
82	Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG and Visvader JE: Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene. 23:7726–7733. 2004. View Article : Google Scholar : PubMed/NCBI
83	Dimitriadis E, Stoikos C, Tan YL and Salamonsen LA: Interleukin 11 signaling components signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) regulate human endometrial stromal cell differentiation. Endocrinol. 147:3809–3817. 2006. View Article : Google Scholar
84	Oktem G, Sanci M, Bilir A, Yildirim Y, Kececi SD, Ayla S and Inan S: Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer. Int J Gynecol Cancer. 22:23–29. 2012. View Article : Google Scholar : PubMed/NCBI
85	Yamada Y, Shigetomi H, Onogi A, Haruta S, Kawaguchi R, Yoshida S, Furukawa N, Nagai A, Tanase Y, Tsunemi T, Oi H and Kobayashi H: Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer. 21:1200–1207. 2011.PubMed/NCBI
86	Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S and Kobayashi H: Molecular genetics and epidemiology of epithelial ovarian cancer. Oncol Rep. 26:1347–1356. 2011.PubMed/NCBI
87	Kato N, Tamura G and Motoyama T: Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary. Virchows Arch. 452:175–180. 2008. View Article : Google Scholar : PubMed/NCBI
88	Shigetomi H, Higashiura Y, Kajihara H and Kobayashi H: A potential link of oxidative stress and cell cycle regulation for development of endometriosis. Gynecol Endocrinol. 28:897–902. 2012. View Article : Google Scholar : PubMed/NCBI
89	Cameron RI, Ashe P, O’Rourke DM, Foster H and McCluggage WG: A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 22:272–276. 2003. View Article : Google Scholar : PubMed/NCBI
90	Brinkman JA and El-Ashry D: ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia. 14:67–78. 2009. View Article : Google Scholar : PubMed/NCBI
91	Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, Takakura S, Yamada K, Okamoto A, Tanaka T and Ohkawa K: Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int J Oncol. 40:2122–2130. 2012.PubMed/NCBI